Literature DB >> 1675367

Medical Research Council European trial of chorion villus sampling. MRC working party on the evaluation pf chorion villus sampling.

.   

Abstract

First-trimester chorion villus sampling has the advantage over second-trimester amniocentesis of allowing earlier prenatal diagnosis of various genetic and cytogenetic disorders in the fetus (and therefore earlier termination in affected pregnancies) but the relative safety and diagnostic accuracy remain unclear. Between 1985 and 1989, 3248 women seeking prenatal diagnosis, principally because of their age, were recruited to an international, multicentre, randomised comparison of the safety and diagnostic accuracy of the two techniques--5% of women allocated chorion villus sampling and 8% of those allocated amniocentesis were not tested, usually because of spontaneous miscarriage. 6% and 2% were retested, in most because of sampling failure. The endpoint of a liveborn infant who survived was achieved by 86% of women allocated chorion villus sampling and 91% of those allocated amniocentesis; statistical analysis, after appropriate weighting for a centre's contribution, showed that the typical difference between the groups was 4.6% (95% confidence interval 1.6-7.5%; p less than 0.01). This difference reflected more spontaneous fetal deaths before 28 weeks' gestation (2.9% [0.6-5.3%]); more terminations of pregnancy for chromosomal anomalies (1.0% [0.0-2.1%]); and more neonatal deaths (0.3% [-0.1 to 0.7%]). The difference in neonatal deaths was due to a preponderance of very immature liveborn infants in the chorion villus sampling group, and this factor also explained that group's longer mean stay in hospital. More abnormal diagnoses followed chorion villus than amniotic fluid analyses (5.6% vs 3.9%). This difference was largely due to diagnoses of trisomy 18 and of (usually mosaic) abnormalities known to be confined to the placenta. 3 terminated pregnancies were false positives, 1 tested by chorion villus sampling and 2 by amniocentesis, and 2 other mosaic cases diagnosed by chorion villus sampling may have been false positives. There was 1 false-negative result in the chorion villus sampling group. The possibility of earlier exclusion or diagnosis of some fetal disorders afforded by first-trimester chorion villus sampling must be set against its clinical risks.

Entities:  

Mesh:

Year:  1991        PMID: 1675367

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Trials and fast changing technologies: the case for tracker studies.

Authors:  R J Lilford; D A Braunholtz; R Greenhalgh; S J Edwards
Journal:  BMJ       Date:  2000-01-01

Review 2.  Chorionic villus sampling (CVS): World Health Organization European Regional Office (WHO/EURO) meeting statement on the use of CVS in prenatal diagnosis.

Authors:  A M Kuliev; B Modell; L Jackson; J L Simpson; B Brambati; G Rhoads; U Froster; Y Verlinsky; S Smidt-Jensen; W Holzgreve
Journal:  J Assist Reprod Genet       Date:  1992-08       Impact factor: 3.412

Review 3.  The prenatal diagnosis of genetic diseases.

Authors:  Peter Wieacker; Johannes Steinhard
Journal:  Dtsch Arztebl Int       Date:  2010-12-03       Impact factor: 5.594

4.  A chimaeric animal model for confined placental mosaicism.

Authors:  R M James; J D West
Journal:  Hum Genet       Date:  1994-05       Impact factor: 4.132

Review 5.  Amniocentesis and chorionic villus sampling for prenatal diagnosis.

Authors:  Zarko Alfirevic; Kate Navaratnam; Faris Mujezinovic
Journal:  Cochrane Database Syst Rev       Date:  2017-09-04

Review 6.  Amniocentesis and chorionic villus sampling for prenatal diagnosis.

Authors:  Z Alfirevic; K Sundberg; S Brigham
Journal:  Cochrane Database Syst Rev       Date:  2003

7.  Evidence-based clinical prioritization of embryos with mosaic results: a systematic review and meta-analysis.

Authors:  Ali Mourad; Roland Antaki; François Bissonnette; Obey Al Baini; Boutros Saadeh; Wael Jamal
Journal:  J Assist Reprod Genet       Date:  2021-09-02       Impact factor: 3.412

8.  Chromosomal mosaicism: Origins and clinical implications in preimplantation and prenatal diagnosis.

Authors:  Brynn Levy; Eva R Hoffmann; Rajiv C McCoy; Francesca R Grati
Journal:  Prenat Diagn       Date:  2021-03-22       Impact factor: 3.050

9.  Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.

Authors:  Artavazd Tadevosyan; Eric J Maclaughlin; Vardan T Karamyan
Journal:  Patient Relat Outcome Meas       Date:  2011-01-25

Review 10.  Chromosomal Mosaicism in Human Feto-Placental Development: Implications for Prenatal Diagnosis.

Authors:  Francesca Romana Grati
Journal:  J Clin Med       Date:  2014-07-24       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.